MLA Diagnostics
Maastricht, Limburg, The Netherlands
About MLA Diagnostics
MLA Diagnostics is developing the Ly75 indicator, a prognostic biomarker that can effectively predict patients’ clinical outcomes. Moreover, the marker is inexpensive, robust, and efficient. Based on the outcome of the MLA Diagnostics biomarker test, patients and physicians can together choose a more effective and personalised treatment path.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Last round: Series Unknown (Nov 2023)
- Website: mladx.com
Industries & Categories
Health Care, Health Diagnostics, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/mla-diagnostics-2526186 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.